Home > News > Dabur Pharma eyes China & Japan entry
August 2nd, 2007
Dabur Pharma eyes China & Japan entry
Abstract:
Domestic anti-cancer drug major Dabur Pharma is finalising plans to enter Japan and China. The company has started the groundwork of filing drug applications and is scouting for potential pharma acquisitions in both the countries.
Dabur Pharma also plans to expand the range of products developed on its nanotechnology drug delivery system, christened ‘Nanoxel'. At the moment, it sells the popular anti-cancer drug ‘Paclitaxel' on this platform. "We also want to export this portfolio of drugs in US, Europe and South-east Asian markets," said Mr Vij.
Source:
economictimes.indiatimes.com
Bookmark:
Nanomedicine
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013
New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Announcements
Competition in the Quantum World May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Penn engineers' nanoantennas improve infrared sensing May 20th, 2013
Researchers Perform Fastest Measurements Ever Made of Ion Channel Proteins May 20th, 2013
Acquisitions/Mergers/Splits
Mincom Capital Inc. and Group Nanoxplore Inc. Sign Letter of Intent for a Qualifying Transaction April 10th, 2013
SUNY NanoCollege and Children's Museum of Science and Technology Announce Agreement for CMOST to Become Part of CNSE: Under CNSE’s leadership, museum will be transformed into a flagship science center to educate in the emerging 21st century science and engineering disciplines February 6th, 2013
Lumineq plant now world’s largest ALD-enabled product factory February 4th, 2013
Nanostart AG reorganizes Asia business: Focus on Asian markets - Launch of 100-percent subsidiary February 4th, 2013